Evidence map›Paper›PMID 37942812›Full record

ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2024

Longitudinal increase of humoral responses after four SARS-CoV-2 vaccinations and infection in MS patients on fingolimod.

Zoé LE van Kempen, Koos Pj van Dam, Jim Bd Keijser, Eileen W Stalman, Laura Yl Kummer, Eva Mm Strijbis, Maurice Steenhuis, Anja Ten Brinke, S Marieke van Ham, Taco Kuijpers and 4 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. T lymphopenia in multiple sclerosis patients treated with ofatumumab: Even with consideration for CD3Multiple sclerosis journal - experimental, translational and clinical
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Zoé LE van KempenDepartment of Neurology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands.ORCID 0000-0001-9557-5381
Koos Pj van DamDepartment of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Amsterdam, The Netherlands.
Jim Bd KeijserDepartment of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam University Medical Centers, Amsterdam, The Netherlands.ORCID 0009-0007-4474-545X
Eileen W StalmanDepartment of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Amsterdam, The Netherlands.
Laura Yl KummerDepartment of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Amsterdam, The Netherlands.
Eva Mm StrijbisDepartment of Neurology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands.ORCID 0000-0001-6705-5864
Maurice SteenhuisDepartment of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
Anja Ten BrinkeDepartment of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
S Marieke van HamDepartment of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
Taco KuijpersDepartment of Pediatric Immunology, Rheumatology and Infectious Disease, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Amsterdam, The Netherlands.
Theo RispensDepartment of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam University Medical Centers, Amsterdam, The Netherlands.ORCID 0000-0001-9600-1312
Filip EftimovDepartment of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Amsterdam, The Netherlands.
Luuk WieskeDepartment of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Amsterdam, The Netherlands.
Joep KillesteinDepartment of Neurology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands.
Sanquin · NLAmsterdam University Medical Centers · NLAmsterdam Neuroscience · NLSt. Antonius Ziekenhuis · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHumoral responses after SARS-CoV-2 vaccination are greatly impaired in multiple sclerosis (MS) patients on fingolimod. Effects of repeated vaccination and infections on long-term responses are unclear.

methodsProspective study in 60 MS patients on fingolimod measuring humoral responses after up to four vaccinations and 8 months after fourth vaccination.

resultsAnti-WH1 antibody titers increased with each additional vaccination. At long-term follow-up titers increased further and most patients developed new humoral responses against the BA.1 omicron variant.

conclusionRepeated SARS-CoV-2 vaccinations boost humoral immunity and, probably together with SARS-CoV-2 infections, induce humoral responses on the long-term in almost all patients.

Indexed as

COVID-19Multiple SclerosisAntibodies, ViralCOVID-19 VaccinesFingolimod HydrochlorideHumansProspective StudiesSARS-CoV-2VaccinationAntibodies, ViralCOVID-19 VaccinesFingolimod HydrochlorideantibodiesCOVID-19immunizationomicronS1P modulators

Identifiers

PMID37942812
PMCPMC10935618
OpenAlexW4388530514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.